Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous Simian/human immunodeficiency virus infection in pigtailed macaques

Journal of Virology

Volumn 75, Issue 5, 2001, Pages 2224-2234

  Cho, M W ^a   Kim, Y B ^a   Lee, M K ^a   Gupta, K C ^a   Ross, W ^a   Plishka, R ^a   Buckler White, A ^a   Igarashi, T ^a   Theodore, T ^a   Byrum, R ^a   Kemp, C ^a   Montefiori, D C ^a   Martin, M A ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 160; RECOMBINANT VACCINE; VACCINIA VACCINE; VIRUS ENVELOPE PROTEIN; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS REACTION; GENETIC VARIABILITY; GLYCOSYLATION; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; IMMUNIZATION; MACACA; NONHUMAN; PRIORITY JOURNAL; PROTECTION; PROTEIN STRUCTURE; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINATION; VIRUS ENVELOPE;

AIDS VACCINES; ANIMALS; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP160; HIV INFECTIONS; HIV-1; MACACA NEMESTRINA; NEUTRALIZATION TESTS; RNA, VIRAL; SAIDS VACCINES; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINATION; VACCINES, SYNTHETIC; VACCINIA VIRUS;

EID: 0035124098     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.75.5.2224-2234.2001     Document Type: Article

References (57)

1. Phenotypic analysis of antigen-specific T lymphocytes
2. Protection from HIV-1 envelope-bearing chimeric simian immunodeficiency virus (SHIV) in rhesus macaques infected with attenuated SIV: Consequences of challenge
3. Fusogenic selectivity of the envelope glycoprotein is a major determinant of human immunodeficiency virus type 1 tropism for CD4+ T-cell lines vs. primary macrophages
4. Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization
5. Immunization with recombinant canarypox vectors expressing membrane-anchored gp120 followed by soluble gp160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1
6. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody
7. Assessment of HIV vaccine development: Past, present, and future
8. Identification of determinants on a dualtropic human immunodeficiency virus type 1 envelope glycoprotein that confer usage of CXCR4
9. Identification of gp120 regions targeted by a highly potent neutralizing antiserum elicited in a chimpanzee inoculated with a primary human immunodeficiency virus type 1 isolate
10. Infection of chimpanzee peripheral blood mononuclear cells by human immunodeficiency virus type 1 requires cooperative interaction between multiple variable regions of gp120
11. Membrane rearrangement and vesicle induction by recombinant poliovirus 2C and 2BC in human cells
12. SF2 recombinant gp120, or both vaccines in seronegative adults
13. Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein
14. Characterization of primary isolate-like variants of simian-human immunodeficiency virus
15. A dual-tropic primary HIV-1 isolate that uses fusin and the β-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors
16. Protection of SIVmac-infected macaque monkeys against superinfection by a simian immunodeficiency virus expressing envelope glycoproteins of H1V type 1
17. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody
18. Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase
19. Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120
20. Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1
21. Immune response of rhesus macaques to recombinant simian immunodeficiency virus gpI30 does not protect from challenge infection
22. Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1
23. Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees
24. Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gpl60 recombinant vaccinia and boosting with rgpl60 in vaccinia-naive adults
25. Neutralizing antibodies against HIV-1 BRU and SF2 isolates generated in mice immunized with recombinant vaccinia virus expressing HIV-1 (BRU) envelope glycoproteins and boosted with homologous gpl60
26. Emergence of a highly pathogenic simian/human immunodeficiency virus in a rhesus macaque treated with anti-CD8 mAb during a primary infection with a nonpathogenic virus
27. Identification of the V1 region as a linear neutralizing epitope of the simian immunodeficiency virus SIVmac envelope glycoprotein
28. Oligomeric modeling and electrostatic analysis of the gpl20 envelope glycoprotein of human immunodeficiency virus
29. Higher Western blot immunoreactivity of glycoprotein 120 from R5 HIV type 1 isolates compared with X4 and X4R5 isolates
30. Passively transferred antibodies directed against conserved regions of SIV envelope protect macaques from SIV infection
31. The construction and characterization of vaccinia virus recombinants expressing foreign genes
32. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies
33. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies
34. Characterization of a human immunodeficiency virus neutralizing monoclonal antibody and mapping of the neutralizing epitope
35. Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors
36. Evaluation of antiviral drugs and neutralizing antibodies to human immunodeficiency virus by a rapid and sensitive microtiter infection assay
37. Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1
38. Probing the structure of the human immunodeficiency virus surface glycoprotein gp120 with a panel of monoclonal antibodies
39. New mammalian expression vectors
40. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA
41. Recombinant modified vaccinia virus ankara expressing the surface gp120 of simian immunodefieiency virus (SIV) primes for a rapid neutralizing antibody response to SIV infection in macaques
42. Protection against HIV-1 infection in hu-PBL-SCID mice by passive immunization with a neutralizing human monoclonal antibody against the gpl20 CD4-binding site
43. Potent neutralization of primary HIV-1 isolates by antibodies directed against epitopes present in the V1/V2 domain of HIV-1 gp120
44. Prevention of H1V-2 and SIVsm infection by passive immunization in cynomolgus monkeys
45. Protection against mucosal SIVsm challenge in macaques infected with a chimeric SIV that expresses HIV type 1 envelope
46. Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120
47. hu-PBL-SCID mice can be protected from HIV-1 infection by passive transfer of monoclonal antibody to the principal neutralizing determinant of envelope gpl20
48. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys
49. Infection and pathogenicity of chimeric simian-human immunodeficiency viruses in macaques: Determinants of high virus loads and CD4 cell killing
50. Resistance of previously infected chimpanzees to successive challenges with a heterologous intraclade B strain of human immunodeficiency virus type 1
51. Live, attenuated simian immunodeficiency virus vaccines elicit potent resistance against a challenge with a human immunodeficiency virus type 1 chimeric virus
52. Antigen presentation and related immunological aspects of HIV-1 vaccines
53. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG
54. Human monoelonal antibody 2G12 defines a distinctive neutralization epitope on the gpl20 glycoprotein of human immunodeficiency virus type 1
55. A novel, glycan-dependent epitope in the V2 domain of human immunodeficiency virus type 1 gp120 is recognized by a highly potent, neutralizing chimpanzee monoclonal antibody
56. In vitro mutagenesis identifies a region within the envelope gene of the human immunodeficiency virus that is critical for infectivity
57. The antigenic structure of the HIV gp120 envelope glycoprotein